[HTML][HTML] Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
YY Shao, WY Shau, ZZ Lin, HM Chen, R Kuo… - European Journal of …, 2013 - Elsevier
PURPOSE: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used
as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of …
as standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of …
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
YY Shao, WY Shau, ZZ Lin… - … journal of cancer …, 2013 - pubmed.ncbi.nlm.nih.gov
Purpose The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used as
standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of the …
standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of the …
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
YY Shao, WY Shau, ZZ Lin, HM Chen, R Kuo… - European Journal of …, 2013 - infona.pl
The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used as standard
salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of the present …
salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of the present …
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
YY Shao, WY Shau, ZZ Lin, HM Chen, R Kuo… - European Journal of …, 2013 - ejcancer.com
Purpose The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used as
standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of the …
standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of the …
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
YY Shao, WY Shau, ZZ Lin, HM Chen, R Kuo… - Eur. J …, 2013 - ntur.lib.ntu.edu.tw
Purpose: The epidermal growth factor receptor inhibitors, gefitinib and erlotinib, are used as
standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of the …
standard salvage therapy for advanced non-small-cell lung cancer (NSCLC). The aim of the …
[引用][C] Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
YY SHAO, WY SHAU, ZZ LIN… - European journal of …, 2013 - pascal-francis.inist.fr
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell
lung cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
lung cancer CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases …
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer.
YY Shao, WY Shau, ZZ Lin, HM Chen… - European Journal of …, 2012 - europepmc.org
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell
lung cancer. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC …
lung cancer. - Abstract - Europe PMC Sign in | Create an account https://orcid.org Europe PMC …
[引用][C] Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer
YY Shao, WY Shau, ZZ Lin, HM Chen, R Kuo… - European Journal of …, 2013 - cir.nii.ac.jp
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell
lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …
lung cancer | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …